A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 372
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CPVT
Long Form : catecholaminergic polymorphic ventricular tachycardia
No. Year Title Co-occurring Abbreviation
2019 A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia family. SCD, WES
2019 A Homozygous CASQ2 Mutation in a Japanese Patient with Catecholaminergic Polymorphic Ventricular Tachycardia. ---
2019 A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. ---
2019 Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. BrS, ECG, LQTS
2019 Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2. CASQ2, iPSC
2019 Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. CPT, EEA-SCA, EST, SCA
2019 Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia. CNV, RYR2, TPS, WT
2019 Ion channel gating in cardiac ryanodine receptors from the arrhythmic RyR2-P2328S mouse. AF, WT
2019 Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. ID, NDDs
10  2019 Plakophilin-2 Truncation Variants in Patients Clinically Diagnosed With Catecholaminergic Polymorphic Ventricular Tachycardia and Decedents With Exercise-Associated Autopsy Negative Sudden Unexplained Death inthe Young. ARVC, gnomAD, PKP2, SUDY
11  2019 Postmortem Findings in a Young Man With Congenital Generalized Lipodystrophy, Type 4 Due to CAVIN1 Mutations. CGL4
12  2019 Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. ---
13  2019 Radiofrequency catheter ablation for drug-refractory atrial tachyarrhythmias in a patient with catecholaminergic polymorphic ventricular tachycardia: A case report. AT, CL, CS, ISP, PVI, PVs, RA, RFCA
14  2019 Ryanodine receptor 2 (RYR2) mutation: A potentially novel neurocardiac calcium channelopathy manifesting as primary generalised epilepsy. GGE, RyR2
15  2019 Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia. ---
16  2018 A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. VT
17  2018 A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia. BB
18  2018 Accelerated idioventricular rhythm degenerating into bidirectional ventricular tachycardia following acute myocardial infarction. AIVR, BVT
19  2018 Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice. EX, HR, SR
20  2018 Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients. iPSC-CMs
21  2018 Asymptomatic ventricular tachycardia: diagnostic pitfalls of Andersen-Tawil syndrome-a case report. ATS
22  2018 Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations. CR, CT, ECG, HRs, LQTS, NT
23  2018 Cardiac Arrest During Spine Surgery in the Prone Position: Case Report and Review of the Literature. CA
24  2018 Catecholaminergic polymorphic ventricular tachycardia managed as orthostatic dysregulation and epilepsy in 11- and 15-year-old sisters. ECG
25  2018 Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry. ACMG, P/LP, VUS
26  2018 Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. ATS, ECG, LBBB, RBBB, VAs, VPBs, VT
27  2018 Differential Diagnosis Between Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome Type 1 - Modified Schwartz Score. EST, LQTS
28  2018 Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. ---
29  2018 EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. CaM, SR
30  2018 Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. ICD, VA
31  2018 Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. CaM
32  2018 Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. ICD
33  2018 Multiple targets for flecainide action: implications for cardiac arrhythmogenesis. AP, BrS, LQTS
34  2018 Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia. CaM, CaMBD, KI
35  2018 Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2. ---
36  2018 Post-Translational Modifications and Diastolic Calcium Leak Associated to the Novel RyR2-D3638A Mutation Lead to CPVT in Patient-Specific hiPSC-Derived Cardiomyocytes. hiPSCs
37  2018 Practice Variation among an International Group of Genetic Counselors on when to Offer Predictive Genetic Testing to Children at Risk of an Inherited Arrhythmia or Cardiomyopathy. ARVC, HCM, LQTS
38  2018 Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. HRQoL, ICD
39  2018 Tetrodotoxin-sensitive Navs contribute to early and delayed afterdepolarizations in long QT arrhythmia models. 4-AP, APD, ATX-II, DADs, EADs, LQT
40  2018 The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. CASQ2, RyR2
41  2018 The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia? NGS, VF, VUS, WES
42  2018 They Are Not Monozygotic Twins - Long QT Syndrome Type 1 (LQT1) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). LQT1
43  2018 Three cases of catecholaminergic polymorphic ventricular tachycardia with prolonged QT intervals including two cases of compound mutations. LQTS, NGS
44  2018 [CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA - CASE REPORT]. SCD
45  2018 [Syncopes and channelopathies]. ECG
46  2017 A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics. ---
47  2017 A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. LVNC, RyR2
48  2017 Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2). AAV9
49  2017 An optogenetic arrhythmia model to study catecholaminergic polymorphic ventricular tachycardia mutations. CASQ2, RyR2, SR
50  2017 Avoiding sports-related sudden cardiac death in children with congenital channelopathy : Recommendations for sports activities. BrS, LQTS, SQTS
51  2017 Catecholaminergic Polymorphic Ventricular Tachycardia - Looking to the Future. PVT
52  2017 Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. RyR2
53  2017 Channelopathies, genetic testing and risk stratification. BrS, ECG, ERS, LQTS, SCD, SQTS
54  2017 Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. CI, OR, OR
55  2017 Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. NGS, RT-PCR, TRDN
56  2017 CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression. ---
57  2017 Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. ---
58  2017 Elimination of Ventricular Arrhythmia in Catecholaminergic Polymorphic Ventricular Tachycardia by Targeting "Catecholamine-Sensitive Area": A Dominant-Subordinate Relationship between Origin Sites of Bidirectional Ventricular Premature Contractions. APM, RBBB, VPCs
59  2017 Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity. RyR2
60  2017 Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. BrS, LQTS, SCD, SQTS
61  2017 Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia-associated variants. ACMG, ExAC
62  2017 Interpreting Incidentally Identified Variants in Genes Associated With Catecholaminergic Polymorphic Ventricular Tachycardia in a Large Cohort of Clinical Whole-Exome Genetic Test Referrals. WES
63  2017 Left cardiac sympathetic denervation: case series and technical report. LCSD, VATS
64  2017 Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations. ASCD, ICD, RyR2, SCD
65  2017 Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease. CCD, MH, RyR
66  2017 RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism. KI, SAN
67  2017 SK4 K+ channels are therapeutic targets for the treatment of cardiac arrhythmias. hiPSC-CMs, KI, SAN
68  2017 Suppression of Arrhythmia by Enhancing Mitochondrial Ca2+ Uptake in Catecholaminergic Ventricular Tachycardia Models. RyR2, VDAC2
69  2017 The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene. CaM, LQTS, SR
70  2017 Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. SR
71  2017 Video-Assisted Thoracoscopic Left Cardiac Sympathetic Denervation in Patients with Hereditary Ventricular Arrhythmias. LCSD, LQTS, VATS
72  2017 [Clinical challenges in the management of catecholaminergic polymorphic ventricular tachycardia in children]. ECG, SCD
73  2017 [Recurrent syncope related to catecholaminergic polymorphic ventricular tachycardia due to de novo RyR2-R2401H mutation]. ---
74  2017 [Ventricular arrhythmias in ion channel diseases]. ICDs, VF, VT
75  2016 A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. iPSC-CMs
76  2016 A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. CASQ2
77  2016 An 88-year-old man with syncope and an alternating axis. ATS, BP, ER
78  2016 Calmodulin 2 Mutation N98S Is Associated with Unexplained Cardiac Arrest in Infants Due to Low Clinical Penetrance Electrical Disorders. IVF, LQTS
79  2016 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations - Long-Term Prognosis After Initiation of Medical Treatment. ESTs, VAs
80  2016 Catecholaminergic Polymorphic Ventricular Tachycardia. ---
81  2016 Catecholaminergic Polymorphic Ventricular Tachycardia. SCD
82  2016 Catecholaminergic polymorphic ventricular tachycardia: An exciting new era. MeSH, NCBI
83  2016 Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. ---
84  2016 Clinical Presentation of Pediatric Patients at Risk for Sudden Cardiac Arrest. LQTS
85  2016 Competitive Sports Participation inPatients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center's Early Experience. ---
86  2016 Constitutive Intracellular Na+ Excess in Purkinje Cells Promotes Arrhythmogenesis at Lower Levels of Stress Than Ventricular Myocytes From Mice With Catecholaminergic Polymorphic Ventricular Tachycardia. PCs, VMs
87  2016 Current topics in catecholaminergic polymorphic ventricular tachycardia. ---
88  2016 Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia. ERP
89  2016 Effective cascade screening through identification of a mutation in RYR2 in a large family with a history of sudden death. ---
90  2016 Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias. AF, RyR
91  2016 Exercise and Inherited Arrhythmias. ARVC, HCM, LQTS, SCD
92  2016 Exercise restrictions for patients with inherited cardiac conditions: Current guidelines, challenges and limitations. BrS, HCM, ICD, LQT1, LQTS, SCD, SQTS
93  2016 Genetic screening in sudden cardiac death in the young can save future lives. BrS1, LQTS, MLPA, SCD, SQTS, SUD
94  2016 Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling. ACM, BTHS, CHD, DCM, FRDA, HCM, hiPSC, HLHS, iPSC, LQT, LS, MFS
95  2016 In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. ---
96  2016 Inherited catecholaminergic polymorphic ventricular tachycardia due to RYR2 mutation. ---
97  2016 Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias. ICD, LCSD, LQTS
98  2016 Molecular autopsy in victims of inherited arrhythmias. BrS, HCM, LQTS, SADS, SCD
99  2016 Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. ---
100  2016 Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia. NOS